Pharmacyclics
Wulff-Erik von Borcke is a highly experienced executive in the pharmaceutical industry, currently serving as Senior Vice President at AbbVie and President of Oncology since January 2020. Prior to this role, Wulff-Erik held the position of President at Pharmacyclics, an AbbVie Company, starting in May 2015. Wulff-Erik also served as Vice President of Global Marketing at AbbVie from January 2013 to April 2015, and held multiple leadership roles at Abbott from April 2001 to December 2012, including Divisional Vice President of Global Marketing for Pharmaceuticals and General Manager for Germany. Earlier career experiences include serving as Director of Immunology at Knoll/BASF Pharma and General Manager for Knoll Slovakia. Wulff-Erik holds a degree in Diplom-Betriebswirt and Graduado Superior en Ciencias Empresariales Europeas from ESB Business School in Germany and Spain.
This person is not in any teams
This person is not in any offices
Pharmacyclics
1 followers
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.